The Priority Review

Tag

IgA Nephropathy

3 stories

Stories

  1. Clinical trials

    Jade Biosciences registers Phase 3 study of JADE101 in IgA nephropathy

    The study, titled the EVERGREEN STUDY, plans to enroll 480 participants and has a planned start date of December 2026. It will evaluate the safety and efficacy of JADE101 versus placebo in adults with immunoglobulin A nephropathy.

  2. Clinical trials

    Novartis registers Phase IIIb trial of zigakibart + atrasentan in primary IgA nephropathy

    This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 340 participants and plans to start December 1, 2026.

  3. Clinical trials

    Results posted for Atacicept study in IgA nephropathy

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study, a Phase 3, randomized, double-blinded, placebo-controlled trial (NCT04716231), enrolled 428 participants and began on June 29, 2023.